Rising expectations from new yeast study

May 23, 2002

Although studying the mating response of brewer's yeast may not stimulate most people, it's exciting stuff to University of Illinois at Chicago biologists David Stone and Metodi Metodiev. In the May 24 issue of the journal Science, they report an important finding about the way cells communicate in the yeast Saccharomyces cerevisiae. The finding may have implications for developing a range of pharmaceuticals, including new cancer treatments.

Saccharomyces cerevisiae has been widely studied and was the first eukaryote to have its genome fully sequenced. What makes this microbe a great research tool is that, although it is simpler than higher eukaryotes, its basic mechanisms of cellular function are the same as those of plant and animal cells, despite a billion years of divergent evolution.

Stone, an associate professor of biological sciences, and Metodiev, a research assistant professor, specialize in signal transduction -- the processes whereby cells consider the many thousands of stimuli they encounter and turn this information into the responses necessary for life. Stone began his study of yeast signal transduction in 1988.

The yeast exists as two mating types, like opposite sexes. Each mating type proliferates rapidly when grown in separate cultures, but when mixed, the opposite types communicate by secreting a chemical love potion called a pheromone. Exposure to pheromone causes the cells to stop dividing, then fuse, or mate.

"To us, the two most important aspects of the mating response are that first, pheromone triggers cells to stop dividing. Second, the cells are able to orient their growth toward the source of pheromone, a process called chemotropism," said Stone. "Growth control is of obvious importance because of its relationship to cancer. Chemotropism is of fundamental importance because we find many chemotropic phenomena in development in adult organisms. For example, our immune systems respond to chemical signals. Whenever we get a wound, immune cells detect the source of chemical signals coming from the wound and migrate toward it. Chemotropism is also relevant to cancer because tumor cells metastasize in response to chemical signals released by specific tissues."

At the molecular level, the yeast mating response works through a series of steps: the signaling pheromone binds to a receptor on the cell membrane, thus activating a signaling molecule called a G-protein. G-protein is made of two parts, G-alpha and G-beta-gamma. G-beta-gamma triggers a sequence of signals along a pathway of enzymes, ending in the activation of a protein called a MAPK, which enters the cell nucleus and affects targets that block cell division.

To resume division, the cells must turn off the mating signal. Exactly how this worked was unclear until Metodiev and Stone, using a research technique called proteomics, discovered that the other part of the G-protein (G-alpha) eventually bypasses this linear signal progression and binds directly to the bottom-level MAPK. It then diverts the MAPK from the nucleus, which allows the growth signal to turn back on. This G-alpha/MAPK binding was previously unknown.

The UIC scientists also discovered that G-alpha lures the MAPK enzymes to the cell's plasma membrane where it works to help orient cell growth toward another cell's chemical signal.

"In contrast to traditional therapies, today's modern drug discovery process is directed at specific proteins and protein-protein interactions," said Metodiev. "In this case, we have demonstrated the interaction of two very important and well-characterized signaling molecules, G-alpha and MAPK. This interaction is a natural target of drug discovery research."

"It's basic scientific research but definitely has the potential to influence therapeutics," said Stone. "There are many human diseases related to problems in controlling cell growth and differentiation. For example, if we know that the metastasis of cancer cells depends on a particular protein-protein interaction, we may be able to develop molecules that block this interaction, and thereby prevent the invasion of healthy tissues."

With further work, Stone and Metodiev hope to determine whether the mechanisms they uncovered in yeast cells operate in human cells. There is evidence suggesting that they do.
-end-
The American Cancer Society and the National Science Foundation supported the research.

Princeton University biologists Dina Matheos and Mark Rose contributed to the research for this paper.

University of Illinois at Chicago

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.